Goldman Sachs Group reissued their neutral rating on shares of Novartis (NYSE:NVS) in a research report released on Wednesday.

A number of other equities research analysts have also recently issued reports on NVS. Zacks Investment Research upgraded Novartis from a sell rating to a hold rating in a research note on Tuesday, June 19th. ValuEngine cut Novartis from a sell rating to a strong sell rating in a research note on Monday, July 2nd. DZ Bank restated a buy rating on shares of Novartis in a research note on Thursday, July 19th. JPMorgan Chase & Co. restated a neutral rating on shares of Novartis in a research note on Thursday, July 19th. Finally, Barclays upgraded Novartis from an underweight rating to an equal weight rating in a research note on Thursday, July 19th. Thirteen equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The stock currently has a consensus rating of Hold and an average target price of $86.90.

Shares of Novartis stock opened at $82.78 on Wednesday. Novartis has a 52-week low of $72.30 and a 52-week high of $94.19. The stock has a market capitalization of $199.67 billion, a P/E ratio of 17.21, a PEG ratio of 1.80 and a beta of 0.83. The company has a current ratio of 1.15, a quick ratio of 0.89 and a debt-to-equity ratio of 0.30.

Novartis (NYSE:NVS) last announced its quarterly earnings data on Wednesday, July 18th. The company reported $1.29 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.27 by $0.02. Novartis had a return on equity of 16.05% and a net margin of 27.06%. The business had revenue of $13.16 billion for the quarter, compared to analysts’ expectations of $12.93 billion. During the same period in the previous year, the business posted $1.22 EPS. The firm’s quarterly revenue was up 7.5% compared to the same quarter last year. As a group, sell-side analysts forecast that Novartis will post 5.17 EPS for the current year.

In other news, major shareholder Bioventures Ltd Novartis sold 12,460 shares of the company’s stock in a transaction dated Wednesday, July 25th. The stock was sold at an average price of $3.84, for a total transaction of $47,846.40. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Over the last quarter, insiders have sold 81,322 shares of company stock worth $290,796. Company insiders own 0.01% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in the company. ST Germain D J Co. Inc. grew its holdings in shares of Novartis by 14.8% during the second quarter. ST Germain D J Co. Inc. now owns 4,765 shares of the company’s stock worth $360,000 after purchasing an additional 615 shares in the last quarter. American Research & Management Co. grew its holdings in shares of Novartis by 1.1% during the second quarter. American Research & Management Co. now owns 57,749 shares of the company’s stock worth $4,362,000 after purchasing an additional 625 shares in the last quarter. King Luther Capital Management Corp grew its holdings in shares of Novartis by 14.3% during the second quarter. King Luther Capital Management Corp now owns 5,175 shares of the company’s stock worth $391,000 after purchasing an additional 649 shares in the last quarter. Wesbanco Bank Inc. grew its holdings in shares of Novartis by 24.2% during the second quarter. Wesbanco Bank Inc. now owns 3,347 shares of the company’s stock worth $253,000 after purchasing an additional 653 shares in the last quarter. Finally, Sterling Capital Management LLC grew its holdings in shares of Novartis by 5.3% during the second quarter. Sterling Capital Management LLC now owns 13,127 shares of the company’s stock worth $992,000 after purchasing an additional 655 shares in the last quarter. Hedge funds and other institutional investors own 10.94% of the company’s stock.

About Novartis

Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for patients and health-care providers. This segment also commercializes products in the areas of oncology and rare diseases, ophthalmology, immunology and dermatology, neuroscience, respiratory, cardio-metabolic, and established medicines.

Featured Article: Investing in Growth Stocks

Analyst Recommendations for Novartis (NYSE:NVS)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.